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Abstract
Background. The impact of multidrug-resistant organisms (MDROs), including non-fermentative bacilli 
(NFBs), is rising and underestimated, especially in intensive care units (ICUs). The growing prevalence of mul-
tidrug resistance (MDR) and extensive drug resistance (XDR) is challenging for clinicians, as the treatment 
options are limited.
Objectives. The purpose of this study was to analyze the extent of the epidemiological problem of multidrug-
resistant, extensively drug-resistant and pandrug-resistant (PDR) non-fermentative bacilli isolated from 
pneumonia and bloodstream infections (BSIs) in patients hospitalized in southern Poland.
Material and methods. This study included 253 NFBs belonging to Acinetobacter sp. (ACI), Pseudomonas sp. 
(PAR), and Stenotrophomonas sp. (STM). The microorganisms were identified, and susceptibility testing was 
performed using a semi-automatic system. The different patterns of resistance were defined as MDR, XDR, 
or PDR strains. Epidemiological typing of A. baumannii from ICUs was performed by repetitive polymerase 
chain reaction (rep-PCR).
Results. More than half of the strains (57.7%) were isolated within ICUs. ACI-strains came significantly 
more often from ICU wards. The highest prevalence of ACI and PAR was found in pneumonia, whereas STM 
dominated in BSIs. ACIs were more frequently resistant than other pathogens to all studied antibiotics except 
colistin (n = 76; 58.9%), and they belonged to the XDR category. DiversiLab demonstrated the presence 
of 2 dominant clones in the ACI group, both classified as European Clone 2 (EUII).
Conclusions. Our results indicate serious potential therapeutic problems related to high antibiotic resistance 
of ACI isolates. The stratification of drug resistance (MDR/XDR/PDR) may become an important tool for the 
assessment of public health epidemiology and microbiological hazards at the local, national, and interna-
tional level. It allows clear presentation of the issues concerning the epidemiology of highly resistant bacilli, 
and the exchange of information between medical staff and local representatives of public health for the 
implementation of effective measures to reduce drug resistance.
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Introduction
The impact of multidrug-resistant organisms (MDROs), 
including non-fermentative bacilli (NFBs), in intensive care 
units (ICUs) is rising and underestimated.1
Pseudomonas aeruginosa (PAR) shows an intrinsic re-
sistance to many antibiotics and can horizontally acquire 
novel resistance genes.2 This may be one of the reasons 
for the increasing number of reports of multi-drug resis-
tant (MDR) strains.3 In particular, nosocomial isolates 
of Acinetobacter and Pseudomonas may exhibit high rates 
of resistance to antimicrobials. Carbapenems are impor-
tant agents for the treatment of severe infections caused 
by P. aeruginosa and A. baumannii. Carbapenem resis-
tance poses a real threat to prognosis, because treatment 
options are limited. Carbapenems are one of the groups 
of antibiotics with enhanced activity, but these agents can 
also be inactivated by various mechanisms.4
Colistin is a key therapeutic option for the treatment 
of carbapenem-resistant A. baumannii and P. aeruginosa, 
alone or in combination with other agents, such as tigecy-
cline, ampicillin–sulbactam, and carbapenems. Monother-
apy is usually recommended for uncomplicated infections, 
while combination therapy is normally recommended for 
severe infections, such as bacteremia and pneumonia, al-
though at least in some cases, the advantage of combina-
tion therapy remains a matter of debate.5 It is supposed 
that colistin resistance emerges under selective pressure 
in individual patients rather than through patient-to-pa-
tient transmission.6 A surveillance study of US hospitals 
revealed that 5.3% of all Acinetobacter strains were resis-
tant to colistin.7
In recent decades, a substantial reduction in mortality 
rates in ICUs has been reported, but the antimicrobial 
resistance profile of microorganisms causing infections 
has significantly changed. Several factors may explain the 
rapid spread of MDROs in ICUs: new mutations, the selec-
tion of resistant strains, and poor antibiotic management. 
Most guidelines have different recommendations depend-
ing on the risk of the presence of MDROs.1,8
Objectives
Modern medicine requires clear and explicit criteria 
to describe the phenomena of public health, and one of the 
major problems of public health is microbial drug resis-
tance. The aim of this study was to analyze the extent 
of the epidemiological problem of highly multidrug-re-
sistant (MDR), extensively drug-resistant (XDR) and pan-
drug-resistant (PDR) non-fermentative bacilli isolated from 
pneumonia and bloodstream infections (BSIs) in patients 
hospitalized in southern Poland.
Material and methods
Population description
This laboratory-based, multicenter study comprised 
consecutive non-repetitive NFB isolates received from 
pneumonia and BSIs, from hospitalized and non-hospi-
talized patients throughout southern Poland (Małopolska 
and Silesia regions), collected between January 1, 2013 
and December 31, 2013. The study included patients from 
12 hospitals, 3 long-term care and outpatient care facili-
ties operated by the Chair of Microbiology at Jagiellonian 
University Medical College (Kraków, Poland), and 2 col-
laborative laboratories from the Silesia region. Pneumonia 
and BSI were diagnosed in accordance with the definitions 
of the European Center for Disease Prevention and Control 
(ECDC).9
A single strain was derived from the first sample col-
lected in the case of the first episode of infection; during 
recurrent infection, a further strain was qualified for the 
study, provided that 14 days had passed since the first epi-
sode of infection, in the absence of clinical symptoms be-
tween the episodes. To confirm a diagnosis of BSI, at least 
2 samples were taken. In the cases when a blood sample was 
taken to confirm a diagnosis of pneumonia, the bacterial 
isolate was treated as the cause of pneumonia (if lacking 
an isolate from bronchoalveolar lavage fluid).
Relevant information about the patients, such as age, 
sex, type of  infection, and place of hospitalization was 
also collected. According to information gathered by the 
collaborating laboratories, patients were classified as one 
of  the following: hospital patients; patients from ICUs 
(n = 146; 57.7%), the Department of Internal Medicine 
(n = 63; 24.9%) or the pulmonary medicine ward (n = 29; 
11.5%); or outpatients, including residents of  long-term 
care facilities (LTCFs), people with infections diagnosed 
by a physician, and those staying in nursing homes or re-
ceiving home care (n = 15; 5.9%). The tested strains came 
from pneumonia (n = 197; 77.9%), BSIs (n = 52; 20.5%) and 
meningoencephalitis (n = 4; 1.6%).
Bacterial isolates
In 2013, 2,763 samples were examined in the collabo-
rating laboratories. Microbiological examinations were 
performed on blood (1,721 samples), pleural puncture 
fluid (124 samples), and tracheobronchial aspirates and 
bronchoalveolar lavage fluid, when available (918 samples).
Microorganisms were identified using a semi-automatic 
system (Phoenix; Becton-Dickinson, Warszawa, Poland), 
according to standard methods. Among the samples test-
ed, 253 were positive for pathogens belonging to NFBs. 
The  studied strains belonged to  the following groups: 
1) ACI (Acinetobacter baumannii, n = 125; Acinetobacter 
junii, n = 1; Acinetobacter radioresistens, n = 1; Acineto-
bacter lwoffii, n = 1; and Acinetobacter ursingii, n = 1); 
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2) PAR (Pseudomonas aeruginosa, n = 86; and Pseudo-
monas putida, n = 4); or 3) Others (Stenotrophomonas 
maltophilia, n = 26; Achromobacter denitrificans, n = 5; 
Comamonas testosteroni, n = 1; Ochrobactrum anthropi, 
n = 1; and Alcaligenes faecalis, n = 1).
Drug resistance
Susceptibility testing was performed using a semi-auto-
matic system (Phoenix NMIC/ID-204; Becton-Dickinson, 
Warszawa, Poland). Antimicrobial susceptibility was as-
sessed according to  the current European Committee 
on Antimicrobial Susceptibility Testing guidelines (EU-
CAST; clinical breakpoint tables v. 5.0),10 and the results 
were considered resistant (R) and susceptible (S). Resistant 
and intermediate strains were grouped together as drug-
resistant. For ampicillin-sulbactam, cefaperozone-sul-
bactam and tetracycline, antimicrobial susceptibility was 
assessed according to the Clinical Laboratory Standards 
Institute guidelines (breakpoints for ampicillin-sulbactam: 
R < 11, I = 12–15, S > 15; for cefaperozone-sulbactam: 
R < 15, I = 16–20, S > 21; for tetracycline: R < 14, I = 15–20, 
S > 21). For all strains, antimicrobial susceptibility testing 
for colistin was performed using the E-test strips (bio-
Mérieux, Warszawa, Poland). Twenty antibiotics from 
11 antimicrobial categories were tested: aminoglyco-
sides, carbapenems, cephalosporins, cephalosporins and 
inhibitors, fluoroquinolones, folate pathway inhibitors, 
monobactams, penicillins, penicillins and β-lactamase 
inhibitors, polymyxins, and tetracyclines. For S. malto-
philia (STM), only trimethoprim-sulfamethoxazole was 
tested, according to the EUCAST guidelines. Resistance 
for an antimicrobial category meant resistance to all an-
timicrobial agents in the category (according to the above 
description).
Different patterns of resistance were defined accord-
ing to Magiorakos et al. with the following modifications: 
1) bacteria not susceptible to at least 1 agent in 3 or more 
antimicrobial categories were considered to  be MDR 
strains; 2) bacteria not susceptible to  at least 1 agent 
in more than 1 or 2 antimicrobial categories were con-
sidered to be XDR strains; and 3) bacteria not susceptible 
to any agents in any antimicrobial categories were consid-
ered to be PDR strains.11
DiversiLab typing
Epidemiological typing of 101 A. baumannii strains from 
2 ICUs (only) was performed by repetitive polymerase 
chain reaction (rep PCR) (DiversiLab System; bioMérieux, 
Warszawa, Poland) as previously described.4 Isolates that 
clustered ≥91.3% were considered related.
Statistical methods
The  differences between 2 groups of  patients with 
an infection caused by Acinetobacter spp. vs Pseudomo-
nas spp. isolates were evaluated with an unpaired t-test 
(Welsh’s t-test). Analysis of variance was used to com-
pare multiple parameters, and their frequency was com-
pared with the χ2 test or G-test (Table 1). The associa-
tion between etiology and the type of  infections, and 
the type of units, etc. was measured with an odds ratio 
(OR) and a 95% confidence interval (CI). Factorial ANO-
VA model (logit link function and Poisson distribution 
of dependent variables) was used to check the influence 
of sex, age and type of ward on the number of antibiotic 
groups for which strains (ACI and PAR) were resistant 
(Table 4). The computer software package Statistica PL 
v. 6.0 was applied, and p < 0.05 was regarded as significant.
Table 1. Characteristics of patients with invasive infection caused by NFB isolates
Origin of the bacterial strains evaluated in the study Acinetobacter spp. (n = 129)
Pseudomonas 
spp. (n = 90)
Others*
(n = 34) p-value Statistical test
Age of patients [years], mean ±SD 60.6 ±17.2 59.9 ±15.2 63.7 ±19.1 0.5291 Student’s t-test
Age of patients depending on the place of hospitalization 
[years], mean ±SD
Department of Internal Medicine (n = 63)
ICU (n = 146)
Pulmonary medicine (n = 29)
outpatients with LTCF residents (n = 15)
67.5 ±16.6
58.2 ±16.7
61.9 ±7.6
72.0 ±8.0
<0.0001 Welsh’s t-test
Sex of patients, male (n; %) 85; 65.9 67; 74.4 22; 64.7 0.3378 χ2
ICU patients (n; %) 101; 78.3 36; 40.0 9; 26.4 <0.0001 G2
Meningoencephalitis (n; %) 4; 3.1 0 0
<0.0001 G2Pneumonia (n; %) 102; 79.0 78; 86.7 17; 50
BSI (n; %) 23; 17.8 1; 13.3 17; 50
NFB – non-fermentative bacilli; ICU – intensive care unit; LTCF – long-term care facility; BSI – bloodstream infection; SD – standard deviation; * Others 
included: Stenotrophomonas maltophilia, n = 26; Achromobacter denitrificans, n = 5; Comamonas testosteroni, n = 1; Ochrobactrum anthropi, n = 1; and 
Alcaligenes faecalis, n = 1.
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Ethics
The use of data collected for scientific purposes of this 
study was approved by the Bioethics Committee of Jagiel-
lonian University Medical College (No. KBET/362/B/2012). 
All data entered into the electronic database and analyzed 
during this research were previously anonymized and 
de-identified.
Results
Study population
The average age of the study population was 60.8 years 
(SD: 16.3  years). There was a  predominance of  males 
(n = 174); however, there was no association between the 
occurrence of microbial species and the sex or age of pa-
tients (Table 1). The age of outpatients differed from the age 
of inpatients and LTCF patients; significantly older patients 
received home care or stayed in LTCFs, and significantly 
younger patients were treated in hospital (Table 1).
ACI strains came significantly more often from ICU 
wards, whereas PAR strains were from pulmonology wards, 
outpatients, and residents of LTCFs (g2 = 52.762; p < 0.0001) 
(Table 1). The tested NFB strains appeared with different 
frequencies in different types of infections. The highest 
prevalence of ACI and PAR was found in pneumonia, and 
STM in BSIs (Table 2). Regardless of the type of unit, PAR 
strains were significantly less frequent in pneumonia than 
ACI (OR: 0.21; 95% CI: 0.133–0.335), and in BSIs, strains 
from the Others group were significantly more frequently 
observed compared with other infections (OR: 4.74; 95% 
CI: 2.208–10.19) (Table 2). Differentiating between ICU 
and non-ICU units, ACI strains were significantly more 
frequent in pneumonia in ICUs than other species (OR: 
5.8; 95% CI: 3.11–10.86) (Table 2). In the case of BSI, there 
were considerably more isolated strains from the Others 
group in non-ICU units than other species (OR: 25.3; 95% 
CI: 4.75–134.89) (Table 2).
Drug resistance
More than 75% of ACI strains were resistant to 14 of 16 anti- 
microbials. Among ACI strains, the proportion of XDR 
strains was the highest among all 3 studied groups of patho-
gens (n = 99; 76.1%), and most of these isolates were resis-
tant to all studied antibiotics with the exception of colistin 
(n = 76; 58.9%) (Table 3). The minimal inhibitory concen-
tration (MIC50) for colistin in the ACI group was 1 mg/L.
Two PAR strains (2.2%) were resistant to all studied 
antibiotics with the exception of netilmicin and colistin. 
XDR PAR strains were less common than XDR ACI, 8.9% 
vs 76.1% (OR: 0.049; 95% CI: 0.022–0.109). MDR strains 
occurred with a  frequency of 28.9% (n = 26) (Table 3). 
The MIC50 for colistin in  the PAR group was 1 mg/L. 
In strains from the Others group, 97% were susceptible 
to sulphametoxazole-trimetoprim (SXT), and only 1 –  
S. maltophilia – was resistant to SXT.
No PDR strains were identified in the studied group. 
Almost 60% of ACI strains were nearly PDR strains, and 
they were susceptible only to polymyxin antimicrobials.
Factorial ANOVA analysis
In the model of factorial analysis, the Poisson distribu-
tion of the dependent variable (effect) and the logit link 
function were assumed. The model showed a significant fit 
(χ2 = 151.5078; df = 9; p < 0.0001). The analysis of param-
eters (Table 4) shows that the NFBs isolated from infec-
tions in ICUs were resistant to more antibiotic groups than 
Table 2. Frequency of isolation of NFB strains in various types of severe 
infection
Infections caused 
by NFB in hospital 
patients Meningitis BSI Pneumonia
ACI
No. 
ICU 3 (75%) 19 (82.6%) 79 (77.5%)
non-ICU 1 (25%) 4 (17.4%) 23 (22.5%)
total 4 (100%) 23 (100%) 102 (100%)
Prevalencea (%) 3.2 1.3 11.1
PAR
No. 
ICU 0 (0%) 8 (66.7%) 28 (35.9%)
non-ICU 0 (0%) 4 (33.3%) 50 (64.1%)
total 0 (0%) 12 (100%) 78 (100%)
Prevalenceb (%) 0.0 0.7 8.5
Others*
No.
ICU 0 (0%) 2 (11.8%) 7 (41.2%)
non-ICU 0 (0%) 15 (88.2%) 10 (58.8%)
total 0 (0%) 17 (100%) 17 (100%)
Prevalencec (%) 0.0 1.0 1.9
ACI – Acinetobacter baumannii; BSI – bloodstream infection; 
ICU – intensive care units; NFB – non-fermentative bacilli; 
PAR – Pseudomonas aeruginosa; * Others included: Stenotrophomonas 
maltophilia, n = 26; Achromobacter denitrificans, n = 5; Comamonas 
testosteroni, n = 1; Ochrobactrum anthropi, n = 1; and Alcaligenes faecalis, 
n = 1;
a  calculated as follows:
(number of ACI meningitis/number of all cerebrospinal fluid 
cultures) × 100%
(number of ACI BSI/number of all blood cultures) × 100%
(number of ACI pneumonia/number of all BAL cultures) × 100%;
b  calculated as follows:
(number of PAR meningitis/number of all cerebrospinal fluid 
cultures) × 100%
(number of PAR BSI/number of all blood cultures) × 100%
(number of PAR pneumonia/number of all BAL cultures) × 100%;
c  calculated as follows:
(number of OTHERS meningitis/number of all cerebrospinal fluid 
cultures) × 100%
(number of OTHERS BSI/number of all blood cultures) × 100%
(number of OTHERS pneumonia/number of all BAL cultures) × 100%;
BAL – bronchoalveolar lavage.
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isolates from other wards. In addition, ACI organisms were 
resistant to more antibiotic groups than the PAR organ-
isms (STM were not considered in the model).
DiversiLab typing
DiversiLab demonstrated the presence of 2 dominant 
clones in the ACI group. Clone 1 included 24 isolates and 
clone 2 included 55 isolates. Both of these clones were clas-
sified as European Clone 2 (EUII). Other listed clones (3–6) 
consisted of 2 strains. Twelve strains were distinguished 
as unique. Two isolates were non-typable. Most isolates 
belonging to clone 1 (67.8%) and clone 2 (80%) were sus-
ceptible only to colistin. Among the unique isolates, 30% 
had a pattern of resistance to colistin alone.
Discussion
Non-fermentative Gram-negative bacilli have emerged 
as major agents of pneumonia (especially ventilator-as-
sociated), and their resistance to antibiotics, particularly 
to carbapenems, has become a therapeutic challenge.
Acinetobacter baumannii has become one of the most 
difficult nosocomial pathogens to control and treat, with 
a mortality rate of ~30%,12 and P. aeruginosa is a highly 
virulent organism with a mortality rate of 40–60%.5 Aci-
netobacter baumannii can also cause bloodstream, urinary 
tract, and wound infections.13
In our study, the highest prevalence of ACI and PAR 
was found in pneumonia, and STM was significantly more 
frequently observed in BSIs.
The most serious issue in the treatment of A. baumannii 
infection are XDR strains, because the number of active 
agents is limited.14 Our study also showed that the greatest 
problem was the extremely drug-resistant A. baumannii 
(76%), compared with MDR strains (14.6%).
The highest resistance among A. baumannii strains 
in our study was observed for aminoglycosides, cepha-
losporins, f luoroquinolones, carbapenems, and SXT. 
According to  the European Antimicrobial Resistance 
Surveillance Network (EARS-Net), antibiotic resistance 
Table 3. Resistance of the type of MDR to a selected group of antibiotics
Antimicrobial (sub-)classes and 
antimicrobials used for testing
Acinetobacter 
spp. 
(n = 129)
Pseudomonas 
spp.
(n = 90)
Aminoglycosides (%)
gentamicin 82.9 28.9
tobramycin 81.4 23.3
amikacin 86.0 30.0
netilmicin 83.7 22.2
Antipseudomonal carbapenems (%)
imipenem 79.8 31.1
meropenem 80.6 38.9
Extended-spectrum cephalosporins (%)
ceftazidime 92.2 25.6
cefepime 92.2 28.9
Antipseudomonal fluoroquinolones (%)
ciprofloxacin 91.5 47.8
levofloxacin 90.7 47.8
penicillins (piperacillin) (%) n/a 26.7
Penicillins and β-lactamase inhibitors (%)
ticarcillin-clavulanic acid n/a 28.9
piperacillin-tazobactam 90.7 24.4 
ampicillin-sulbactam 77.5 n/a
monobactams (%) n/a 96.7
folate pathway inhibitors (%) 91.5 n/a
tetracyclines (%) 89.9 n/a
cephalosporins and inhibitors (%) n/a 17.8
Polymyxins (%)
colistin 0.0 0.0
Type of resistance
sensitive (%) 5.4 27.8
MDR (%) 14.6 28.9
XDR (%) 76.1 8.9
PDR (%) 0.0 0.0
Other (%) 3.9 34.4
MDR – multidrug-resistant; XDR – extensively drug-resistant;  
PDR – pandrug-resistant; n/a – not applicable.
Table 4. Independent predictors of antimicrobial resistance: Factorial ANOVA analysis
Estimate Std Err L-R χ2 p-value
Age of patients      0.000262 0.002001   0.017154 0.8958
Type of patient care: internal medicine      0.140364 0.178104   0.703742 0.4015
Type of patient care: intensive care units      0.406582 0.167152   9.066479 0.0026
Type of patient care: outpatients −0.37352 0.304834   1.507221 0.2196
Type of patient care: pulmonary medicine −0.08715 0.1922   0.192896 0.6605
Sex of patients: male −0.03265 0.036124   0.822937 0.3643
Studied non-fermentative bacilli: ACI      0.322053 0.041334 66.68041 <0.0001
ACI – Acinetobacter baumannii; Std Err – standard error; L-R – likelihood ratio.
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in Acinetobacter species shows large variations across 
Europe, with generally high percentages of  resistance 
reported in  southern Europe and lower percentages 
in northern Europe. Combined resistance to fluoroqui-
nolones, aminoglycosides and carbapenems was ≥20% 
in 12 of the 23 countries reporting susceptibility results 
for 10 or more isolates. Carbapenem-resistant A. bauman-
nii reached >25% in 8 of the 18 countries reporting data. 
Resistance to polymyxins, a group of last-line antibiotics, 
was observed in 5% of the isolates, mostly from southern 
Europe.15
In 2010, the European Centre for Disease Prevention 
and Control (ECDC) reported that ~15% of P. aeruginosa 
strains were MDR, in contrast to 1993, when the reported 
value was only 4%.16 It is worrying to note that 1/3 of the 
isolates were MDR, and 8.9% were XDR. Taken together, 
this means that ~40% of the population are at risk of seri-
ous problems with the treatment of severe infections, such 
as BSI and pneumonia.
According to EARS-Net, ~32.3% of the PAR isolates from 
invasive infections in 2013 were carbapenem-resistant, 
which is comparable to our results (about 1/3 of the stud-
ied strains were resistant to imipenem). This is more than 
in previous reports from Poland, where only 10.5% of the 
isolates were carbapenem-resistant.17
We also noted a high number of PAR strains resistant 
to aminoglycosides (~30%). Such a problem does not ex-
ist in countries such as Sweden (3%) or Norway (1.5%), 
but the situation is different in Greece (40%) or the Czech 
Republic (25%).15
The percentage of strains resistant to fluoroquinolones 
is also worrying, as about half of the tested strains were 
resistant. This rate is also higher than in Scandinavian 
countries, where <10% of strains isolated from invasive in-
fections are resistant to those antimicrobials. Furthermore, 
attention should be paid to the use of fluoroquinolones. 
Similar results were obtained in the case of urinary tract 
infections caused by PAR in Poland, which is understand-
able, as those antimicrobials are intended for use in urinary 
tract infections.18
Carbapenem-resistant strains are mostly susceptible 
to polymyxins; however, these antimicrobials are known 
to be toxic and are used as drugs of last resort. In our study, 
the greatest therapeutic problem was represented by the 
strains that were nearly pandrug-resistant and susceptible 
only to colistin. No strains resistant to colistin were re-
ported in Poland.
It is of particular interest that, in our study, BSIs were 
frequently caused by bacteria from the OTHERS group, 
mainly STM. The World Health Organization (WHO) clas-
sified this pathogen as one of the leading MDROs in hos-
pital settings.19 STM causes a wide range of infections, 
including respiratory tract infections and BSIs. Despite the 
large number of different global surveillance studies, there 
are still limited data on the prevalence and susceptibil-
ity patterns of STM.20 The worldwide prevalence of STM 
in BSIs was ~0.8% in 2000–2004.21 It is difficult to assess 
how large the problem with STM was in our study popula-
tion, because there were no data from other multicenter 
studies. However, reports from the German KISS program 
show a growing involvement of STM in the etiology of hos-
pital infections, and the proportion of STM increased from 
1.646 to 2.102 between 2001 and 2004.21
There are limited antimicrobial options for infections 
due to STM because of its extensive resistance to most 
antibiotics. One drug recommended as a drug of choice 
is SXT.22 Resistance rates may vary between different re-
gions but, in general, they are <10%.23,24 One study from 
Poland on a set of 80 STM clinical isolates showed that 
only 71.3% of the strains were susceptible to SXT.25 Here, 
we detected only 1 resistant strain, which is not consistent 
with previous reports.
Conclusions
Our results indicate serious potential therapeutic prob-
lems related to the high antibiotic resistance of A. bau- 
mannii isolates. The  stratification of  drug resistance 
(MDR/XDR/PDR) may become an important tool for the 
assessment of public health epidemiology and microbio-
logical hazards at the local, national, and international 
levels. It allows a clear presentation of the issues concern-
ing the epidemiology of highly resistant bacilli, and the 
exchange of information between medical staff and local 
representatives of public health for the implementation 
of effective measures to reduce drug resistance. The grow-
ing prevalence of MDR and XDR is challenging for cli-
nicians, because the treatment options are limited. New 
antimicrobial agents and treatment protocols are needed.
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